Lymphoma & Plasma Cell Disorders
News
Diabetics have higher risk of hematologic, other cancers
A review of data from more than 19 million people indicates that diabetes significantly raises a person’s risk of developing cancer. When...
Conference Coverage
Adding elotuzumab improves myeloma PFS over pom/dex alone
STOCKHOLM – Elotuzumab, pomalidomide, and dexamethasone improved progression-free survival and responses, compared with pom/dex alone in patients...
News
PET-guided treatment didn’t improve outcomes
In the PETAL trial, treatment intensification based on results of an interim positron emission tomography (PET) scan did not improve survival...
News
Mutations linked to higher risk of SNs in CCSs
New research has shown that childhood cancer survivors (CCSs) with certain germline mutations have higher relative rates (RRs) of secondary...
CME
CAR T Therapy: From Bench to Bedside and Back
From the Journals
New guideline for managing MCL
Feature
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
Conference Coverage
Ibrutinib/venetoclax shows early promise in relapsed CLL
STOCKHOLM – An ongoing study shows a high clinical response rate and acceptable safety profile with the chemotherapy-free targeted therapy...
News
New approach to AE reporting needed, group says
A group of experts has called for improvements in reporting adverse events (AEs) that occur in patients with hematologic malignancies. The group...
News
Health Canada expands approval of obinutuzumab
Health Canada has expanded the approved use of obinutuzumab (Gazyva®). The anti-CD20 monoclonal antibody is now approved for use in combination...
News
ESMO, ASCO seek improved cancer services
The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) have called for renewed political commitment...